公开(公告)号：US09993539B2

公开(公告)日：2018-06-12

申请号：US15637906

申请日：2017-06-29

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Phillip Mueller ,  Julia Leibold ,  Valentina Goldfinger

IPC: A61K39/00 ,  G01N33/68

CPC classification number: A61K39/0011 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/30 ,  C07K2319/00 ,  C12N5/0636 ,  C12N15/115 ,  C12N2310/16 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/57407 ,  G01N33/5748 ,  G01N33/6848 ,  G01N2570/00 ,  G01N2800/52

Abstract: A method of treating a patient who has liver cancer (HCC), breast cancer (BRCA), melanoma, and/or uterine cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, BRCA, melanoma, and/or uterine cancer.

公开(公告)号：US20170326215A1

公开(公告)日：2017-11-16

申请号：US15637906

申请日：2017-06-29

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreef Singh ,  Phillip Mueller ,  Julia Leibold ,  Valentina Goldfinger

IPC: A61K39/00 ,  G01N33/68

CPC classification number: A61K39/0011 ,  A61K38/00 ,  A61K2039/5158 ,  A61K2039/572 ,  C07K14/47 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/30 ,  C07K2319/00 ,  C12N5/0636 ,  C12N15/115 ,  C12N2310/16 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/57407 ,  G01N33/5748 ,  G01N33/6848 ,  G01N2570/00 ,  G01N2800/52

Abstract: A method of treating a patient who has liver cancer (HCC), breast cancer (BRCA), melanoma, and/or uterine cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, BRCA, melanoma, and/or uterine cancer. A method of treating a patient who has HCC, BRCA, melanoma, and/or uterine cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, BRCA, melanoma, and/or uterine cancer.